Similar Search Results

Pharmaceutical Sector in Serbia in the Period 1990-2013 (ФАРМАЦЕУТСКИ СЕКТОР У СРБИЈИ ОД 1990. ДО 2013. ГОДИНЕ)

Dragutinovic, Stefan; Zubovic, Jovan; Reljic, Marija - 2015

English Abstract: In this paper authors give an overview of the development of the pharmaceutical industry in former Yugoslavia and Serbia in the period 1990-2013. The aim is to examine whether pharmaceutical industry, which was largely fragmented at the beginning of 90’s, after a decade of...

Persistent link: https://www.econbiz.de/10014138435

Reducing Import Dependence on APIs in the Indian Pharmaceuticals Sector : An Analysis of Early Experience of the PLI Phase-I Scheme

Joseph, Reji K.; Arun Kumar, Ramaa - 2022

The outbreak of COVID-19 in Wuhan, China and the lockdown that followed had disrupted the supply of APIs and their intermediates and starting materials to India, leading to a temporary restriction on export of certain medicines from India. The PLI scheme that was announced subsequently aimed at...

Persistent link: https://www.econbiz.de/10013297643

Pricing Intermediaries in Prescription Drug Markets : To Leverage or Replace?

Feng, Josh - 2020

This article assesses the price-negotiation role played by Pharmacy Benefit Managers (PBMs), which have been at the heart of the recent drug pricing debate. I start by collecting novel data on the net-of-rebate prices of anti-cholesterol drugs. These prices are then used to estimate a dynamic...

Persistent link: https://www.econbiz.de/10012850411

A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration

Ching, Andrew T. - 2012

Motivated by the slow diffusion of generic drugs and the increase in prices of brand-name drugs after generic entry, I incorporate consumer learning and consumer heterogeneity into an empirical dynamic oligopoly model. In the model, firms choose prices to maximize their expected total discounted...

Persistent link: https://www.econbiz.de/10012755155

Regulation and Pricing of Pharmaceuticals : Reference Pricing or Price Cap Regulation?

Brekke, Kurt Richard; Grasdal, Astrid; Holmas, Tor Helge - 2021

-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …

Persistent link: https://www.econbiz.de/10013316907

Regulation, Generic Competition and Pharmaceutical Prices : Theory and Evidence from a Natural Experiment

Brekke, Kurt Richard; Holmas, Tor Helge; Straume, Odd Rune - 2014

We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level...

Persistent link: https://www.econbiz.de/10014198115

Consumer Learning and Heterogeneity : Dynamics of Demand for Prescription Drugs after Patent Expiration

Ching, Andrew T. - 2012

This paper investigates whether aggregate consumer learning together with consumer heterogeneity in price sensitivity could explain why (i) there is a slow diffusion of generic drugs into the market, and (ii) brand-name originators keep increasing their prices over time even after the number of...

Persistent link: https://www.econbiz.de/10014047796

The Information Prescription for Drug Regulation

Bernstein, Anita; Bernstein, Joseph - 2013

Before it can sell a prescription drug lawfully in interstate commerce, a manufacturer must prove to the satisfaction of the Food and Drug Administration that the drug is both safe and effective. Congress approved this requirement in 1962 unanimously. Four decades of changes in the drug market...

Persistent link: https://www.econbiz.de/10014058315

Auditing the Prescription Drug Consumer Price Index in a Changing Marketplace

Frank, Richard G.; Hicks, Andrew; Berndt, Ernst R. - National Bureau of Economic Research - 2022

prescription pharmaceuticals dispensed in hospitals, physician/clinic outpatient facilities, and nursing homes. Thus the CPI …-Rx overlooks the increasingly important specialty pharmaceuticals dispensed in hospitals, outpatient clinics, and physician offices … drug growth differs from that of traditional pharmaceuticals, the CPI-Rx could provide an inaccurate measure of overall …

Persistent link: https://www.econbiz.de/10013388804

Exploring the feasibility of sharing information on medicine prices across countries

Moens, Marjolijn - 2024

In recent years, the call for transparency in pharmaceutical pricing has gained momentum among policymakers and stakeholders. Following a resolution of the 72nd World Health Assembly and the establishment of the Oslo Medicines Initiative, there has been a concerted push for greater transparency...

Persistent link: https://www.econbiz.de/10015081483